Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for women with infertility having IVF/ICSI with a long GnRH agonist protocol, whose LH level becomes very low. It tests whether adding LH improves embryo quality.

Életkor

20 to 37 years

Nem

Women only

A betegség stádiuma

Infertility treated with IVF/ICSI using the long-acting GnRH agonist protocol. Normal womb cavity, checked by hysteroscopy, sonohysterography or hysterosalpingography within 6 months.

Korábbi kezelés

Must be having the long-acting GnRH agonist protocol. People with a history of ovarian surgery cannot join.

Biomarker vagy leletérték

Blood LH level <0.5 U/L after pituitary downregulation.

A részvétel fő kizáró okai

• Polycystic ovary syndrome (PCOS), endometriosis or adenomyosis
• Repeated failure of embryos to implant (RIF)
• Ovarian cysts ≥3 cm (1,2 in) or suspected cancer; history of ovarian surgery
• Low egg reserve (antral follicle count <5, anti-Müllerian hormone <1.1 ng/mL, or baseline FSH >10 IU/L)
• Chromosome changes in either partner, or uncontrolled high blood pressure, diabetes, thyroid or autoimmune disease

A regiszter feltételei, szó szerint

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

• 20 és 37 év között vagy?IgenNem

Mit akar kideríteni a vizsgálat

This randomized controlled trial aims to evaluate whether supplementation with exogenous luteinizing hormone (LH) can improve embryo quality in patients undergoing in vitro fertilization (IVF) with a long gonadotropin-releasing hormone agonist (GnRH-a) protocol who have excessive suppression of LH. Eligible participants will be randomly assigned to receive either exogenous LH supplementation or standard care. The primary outcome is embryo quality, and secondary outcomes include pregnancy rates and safety assessments. The study is conducted at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University.

A vizsgálat 2 csoportja

• Recombinant LH Supplementation GroupA vizsgált kezelés

  Participants receive controlled ovarian hyperstimulation (COH) using a long-acting GnRH agonist (triptorelin 3.75 mg) for pituitary downregulation, followed by recombinant FSH (rFSH) combined with recombinant LH (rLH) at a ratio of 2:1 starting on stimulation day. rLH administration continues throughout the stimulation phase, with gonadotropin doses adjusted based on follicular growth and hormone monitoring. Trigger is given when 2-3 leading follicles reach ≥18 mm, followed by oocyte retrieval, IVF/ICSI, and embryo quality assessment.

  Kezelés: Recombinant Luteinizing Hormone (rLH), Recombinant Follicle-Stimulating Hormone (rFSH) és Gonadotropin-Releasing Hormone Agonist (GnRH-a)

• Conventional rFSH-Only GroupMár használt kezelés, összehasonlításként

  Participants receive the same long-acting GnRH agonist downregulation and rFSH stimulation protocol as the experimental arm, but without rLH supplementation. Only rFSH is used during COH, with dose adjustments according to follicular development and hormone levels. Trigger, oocyte retrieval, IVF/ICSI, and embryo assessment follow the same procedures as in the experimental arm.

  Kezelés: Recombinant Follicle-Stimulating Hormone (rFSH) és Gonadotropin-Releasing Hormone Agonist (GnRH-a)